My watch list
my.bionity.com  
Login  

Vanda Pharmaceuticals Inc. (VNDA) - Financial and Strategic SWOT Analysis Review

Vanda Pharmaceuticals Inc. (Vanda), is a biopharmaceutical company, engaged in developing and commercializing clinical-stage drug candidates targeting central nervous system disorders. Recently, the company and its development partner Novartis Pharmaceuticals Corporation have launched Fanapt (iloperidone) in the US. Fanapt was approved by the US Food and Drug Administration (FDA) in 2009 for the treatment of schizophrenia in adults. Fanapt (iloperidone) is a mixed dopamine D2 / serotonin 5HT2A receptor antagonist for the acute treatment of adult patients with schizophrenia. In addition, the company has completed Phase III clinical trials of Tasimelteon (VEC-162) for treating circadian rhythm sleep disorders (CRSD). During 2010, FDA granted orphan drug designation status for tasimelteon in a specific CRSD. Vanda is headquartered at Rockville in Maryland, the US.

Vanda Pharmaceuticals Inc. Key Recent Developments

Aug 05, 2010: Vanda Reports Net Income Of $1.3 Million For Q2 2010
Feb 10, 2011: Vanda Reports Net Income Of $2.2m For Q4 2010
Nov 03, 2010: Vanda Reports Net Income Of $3.2 Million For Q3 2010
Nov 12, 2010: Vanda Appoints James Kelly As CFO
Nov 15, 2010: Vanda Receives Positive Ruling From IRS

This comprehensive SWOT profile of Vanda Pharmaceuticals Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Vanda Pharmaceuticals Inc. including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Report Highlights
Ortho-McNeil-Janssen Pharmaceuticals, Inc.
AstraZeneca PLC
Otsuka Pharmaceutical Co., Ltd.
Schering-Plough Pty Limited
Takeda Pharmaceuticals North America, Inc.
Sepracor Inc.

Pharmacy / Drugs   Market study
Year:   2011
Publisher:   GlobalData
Price:   250.00€
More about GlobalData
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE